Intrinsic Imaging
Oncology radiologist reviewing a chest CT with a highlighted lung tumor lesion

Oncology Imaging Core Lab Division

Intrinsic Imaging provides imaging core lab services in support of oncology clinical trials. Our oncology radiologists pair standardized tumor response assessment with advanced quantitative imaging, allowing sponsors to evaluate safety and efficacy in oncology and immuno-oncology with confidence. Having participated in hundreds of Phase I through IV oncology clinical trials, Intrinsic Imaging brings experience that spans a broad spectrum of cancer indications, imaging modalities, therapeutic mechanisms and study designs.

At Intrinsic Imaging, our Oncology Imaging division brings together more than 180 board-certified radiologists focused in oncology, with clinical trial imaging experience across solid tumors and hematologic malignancies. Our readers assess tumor response using established and emerging oncology criteria, including RECIST 1.1, iRECIST, mRECIST, Lugano, Cheson, RANO, PERCIST, Choi, PCWG-2, BI-RADS, and other indication- and protocol-specific methodologies.

Intrinsic Imaging supports oncology imaging endpoints across CT, MRI, PET/CT, SPECT, bone scintigraphy, and ultrasound, including diffusion, perfusion, volumetric, and quantitative PET methods. Our teams work closely with sponsors from protocol and imaging charter development through regulatory-ready data delivery to qualify imaging sites, standardize acquisition, maintain image quality control, conduct blinded independent central review (BICR) with adjudication, and perform quantitative analysis.

By combining subspecialty readers, consistently applied response criteria, and centralized quality control, Intrinsic Imaging helps sponsors protect the integrity of critical oncology endpoints and make confident clinical and regulatory decisions. This quality-controlled core lab infrastructure is backed by three FDA inspections with zero Form 483 observations and five ISO certifications.

Oncology Imaging Division Highlights

  • Extensive experience in providing services in support of oncology and immuno-oncology clinical trials.
  • 180+ board-certified radiologists focused in Oncology.
  • Participated in hundreds of Phase I through IV Oncology clinical trials for both safety and efficacy.
  • Expertise includes the full spectrum of oncology and immuno-oncology imaging indications and assessments.
  • Experts in all Oncology Criteria: BI-RADS, Cheson, Choi, irRC, iRECIST, IWCLL, Lugano, Macdonald, mRECIST, PCWG-2, PERCIST, RANO, RECIST and others.
  • Modality expertise includes: CT, MRI, PET/CT, SPECT, bone scintigraphy and ultrasound.
  • Integrated CRF with multiple criteria support.

Blinded Independent Central Review (BICR)

At Intrinsic Imaging, board-certified radiologists focused in oncology conduct blinded independent central review with adjudication, reducing reader variability and bias in oncology trials. Readers are trained and qualified on each protocol's imaging charter, and every review follows standardized methodologies with integrated data capture.

Tumor Response Criteria: RECIST 1.1 and Beyond

Intrinsic Imaging's tumor response assessments extend from RECIST 1.1 for solid tumors to criteria for immunotherapy (iRECIST, irRC), lymphoma (Lugano, Cheson), neuro-oncology (RANO, Macdonald), prostate cancer (PCWG-2), and metabolic response (PERCIST). Our integrated case report forms support multiple criteria within a single study, with the response rules and results of each framework kept independent and traceable.

Tumor measurements are imaging biomarkers that drive key oncology endpoints such as objective response rate (ORR) and progression-free survival (PFS). Intrinsic Imaging's readers apply each protocol's response criteria the same way at every timepoint, keeping these imaging endpoints consistent across sites, scanners, and readers.

Indication-Specific Oncology Imaging and Response Criteria

Intrinsic Imaging's oncology imaging core lab selects the acquisition method, response criteria, and independent review design around the tumor type and treatment. The imaging charter then defines baseline eligibility, lesion selection, follow-up timing, and response rules before central review begins, keeping every assessment within a prespecified framework.

Trial settingImaging and criteriaCentral assessment
Solid tumorsCT and MRI; RECIST 1.1Target and non-target lesions, new lesions, best response, progression
Immuno-oncologyCT and MRI; iRECIST and immune-response criteriaUnconfirmed and confirmed progression per protocol timing
LymphomaFDG PET/CT and CT; Lugano and Deauville five-point scaleMetabolic and anatomic response, nodal and extranodal disease
Neuro-oncologyContrast-enhanced MRI; RANO and RANO 2.0Enhancing and non-enhancing disease, clinical and steroid use
Prostate cancerCT, MRI and bone scintigraphy; PCWG3Soft-tissue response and bone progression with protocol confirmation
Hepatocellular carcinomaMultiphase CT and MRI; mRECISTViable enhancing tumor rather than total lesion size alone
Gastrointestinal stromal tumorsCT; Choi criteriaChanges in tumor size and attenuation
Metabolic responseFDG PET/CT; PERCISTStandardized uptake with acquisition and reconstruction controls

Quantitative Imaging Biomarkers and Radiomics

Intrinsic Imaging measures lesion dimensions, tumor volume, diffusion-derived apparent diffusion coefficient (ADC), perfusion, and PET uptake for efficacy and exploratory biomarker analyses. Radiomics support includes lesion segmentation, extraction of quantitative image features, and reproducibility checks across scanners and acquisition settings. Feature definitions and analysis methods are specified before analysis begins to limit avoidable bias.

Intrinsic Imaging's central assessments inform endpoints such as objective response rate, duration of response, and progression-free survival. The protocol defines how central imaging results are combined with clinical data, as imaging alone does not establish overall survival or patient benefit.

Reader Agreement, Adjudication and Longitudinal Consistency

Before production reads begin, Intrinsic Imaging's readers qualify on the study criteria and representative cases. Independent reviewers then follow a defined longitudinal reading sequence, with blinding rules that control access to treatment assignment, site assessments, and other information that could bias interpretation.

Intrinsic Imaging tracks discrepancies in lesion selection, response category, and progression timing, and an independent adjudicator resolves disagreements according to the charter. Reader agreement and drift reviews identify where calibration or retraining is needed, while an audit trail preserves the original assessments and the adjudicated results.

PET/CT and Multicenter Acquisition Controls

Intrinsic Imaging's site instructions specify scan coverage, slice thickness, contrast timing, and follow-up consistency, so that lesions are measured on comparable images across sites and timepoints. PET controls address uptake time, glucose documentation, scanner calibration, and reconstruction. Quality control confirms that each examination is suitable for the intended endpoint and records missing scans, non-evaluable images, and site queries.

Guidance for Sponsors

Physician-authored guidance from Intrinsic Imaging on imaging endpoints and trial design.

Illustration of dividing cancer cells

Guidance for Sponsors · Volume 4, Issue 3 · 2026 Edition

Oncologic Imaging: The Benefits of Diffusion-Weighted MRI

Diffusion-weighted MRI (DWI) was first used to greatest advantage in stroke imaging. Advances in gradients and pulse sequences have since made it a core tool for detecting, characterizing and following malignant lesions in the chest, abdomen and pelvis. Today it is the dominant sequence for peripheral-zone prostate cancer, a foundation of whole-body MRI for bone and marrow disease, and, through the apparent diffusion coefficient (ADC), a quantitative biomarker with published repeatability standards. For sponsors, DWI offers a fast, contrast-free measure of tumor cellularity and treatment response, provided acquisition and analysis are standardized across sites.

Read the article
Illustration of the lungs and airways

Guidance for Sponsors · Volume 4, Issue 6 · 2026 Edition

The Challenges of Reducing Lung Cancer Mortality with Screening

Lung cancer remains the leading cause of cancer death in the United States. Two large randomized trials, NLST and NELSON, have shown that low-dose CT (LDCT) screening reduces lung cancer mortality, and U.S. eligibility was broadened in 2021. Yet the challenges that shaped the first edition of this issue remain: false positives, overdiagnosis, radiation, and the biases that can make screening look more effective than it is. Artificial intelligence for nodule detection and characterization adds new opportunity, and new questions that only well-designed trials can answer.

Read the article
Illustration of tumor cells

Guidance for Sponsors · Volume 5, Issue 1 · 2026 Edition

Immunotherapy and Imaging of Metastatic Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma remains one of the most lethal cancers, with a five-year relative survival of 13% and a rising share of U.S. cancer deaths. After a decade in which checkpoint immunotherapy largely failed in this disease, the therapeutic landscape is finally changing: a new first-line chemotherapy regimen has been approved, and in 2026 an oral RAS inhibitor doubled overall survival in a Phase 3 trial of previously treated patients. These advances raise the stakes for imaging. Contrast-enhanced CT, MRI and FDG-PET/CT must deliver staging and response data that are standardized, reproducible and interpretable under the right criteria, including iRECIST when immunotherapy is involved.

Read the article

More guidance: NSCLC Imaging Advances; Brain Tumor Imaging in Trials; CLL Imaging in Clinical Trials; Colorectal Liver Metastases Imaging in Trials; WHO, RECIST, mRECIST and Cheson Criteria

Browse all Guidance for Sponsors →

Featured Case Study

Intrinsic Imaging

Oncology

Phase III Immunotherapy RECIST and iRECIST

  • 90+ sites in 18 countries
  • CT, MRI
  • RECIST 1.1 and iRECIST

Challenge

Immunotherapy trials present a distinctive interpretive challenge: apparent radiographic progression may reflect treatment-related inflammation rather than true tumor growth. The sponsor required central reviewers to distinguish pseudoprogression from genuine disease progression with consistency across more than 90 sites in 18 countries, while applying two response frameworks—RECIST 1.1 and iRECIST—in parallel. Any variability in how unconfirmed progression was identified, confirmed, or dated threatened to distort the trial's efficacy conclusions and invite regulatory scrutiny.

Read the case study
View all case studies

More Oncology case studies

Frequently Asked Questions

How can I find an Intrinsic Imaging case study relevant to my trial?
Intrinsic Imaging organizes case studies by category so that sponsors can focus on a therapeutic area or study type. When reviewing Intrinsic Imaging’s case studies, sponsors should also consider the imaging endpoint, acquisition modality, reader design and operational challenge, rather than the indication alone.
What happens to the imaging charter when the protocol is amended?
Intrinsic Imaging assesses the amendment, revises the imaging charter under document control, and records what changed and when the change took effect. Reviewers are retrained on the revised imaging charter, and each training record identifies the version that applies.
What trial experience do Intrinsic Imaging’s ophthalmology specialists bring?
Intrinsic Imaging’s board-certified ophthalmologists have participated in more than 160 ophthalmology clinical trials as principal investigators or reviewers.
Go to more Frequently Asked Questions

Tell us about your trial.

Planning an Oncology trial? Our team will respond within one business day.